Sareum shares rocket after ProNAi Therapeutics licenses cancer drug
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 11 of 12
Risers & Fallers: Sareum, LPA Group, Universe ...
The major share price risers and fallers in London at 9.45am
FTSE 100 stocks end softer as pound remains lowly
FTSE 100 stocks ended softer on Tuesday as sterling remained nestled near to post-Brexit lows for a second successive session
Proactive news highlights: Forbidden Technologies, Netscientific, Rare Earth, StatPro and more...
Telit is collaborating with Indian information tech specialist, Vortex Biosciences granted licences for cell electroporation and Forbidden Technologies signs with a sports content group.
Investments and investor services
Risers & Fallers: Acorn Minerals, LivaNova, Thor ...
Investors have subscribed for 16.5mln Acorn Minerals shares at 15p a pop, raising the company £2.48mln. Shares rose to 13.25p.
Sareum Holdings reinforces patent protection in China and Hong Kong
The firm received similar patents the USA and Europe in September last year.
Proactive news highlights: 88 Energy, Caledonia Mining, FairFX, Minds + Machines and more...
Sareum Holdings plays down a recent report, Eurasia Mining agrees a refining contract and Minds + Machines is seeing exceptional growth.
Trending: British Gas feeling the heat
British Gas has lost 399,000 customers ... perhaps they are still there, they just weren't in when the company called.
Sareum plays down cancer treatment report
Shares in Sareum jumped nearly 20% yesterday as investors latched onto to an article published earlier this month
Sareum marks progress with 'better-than-expected' profit
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Sareum boosted by impending Phase I trials
Two trials are expected to open in collaboration with partner the CRT Pioneer Fund, at the Royal Marsden Hospital, Sutton on May 31 this year.
Change in the chair at Sareum
Dr Parker currently sits on the boards of Silence Therapeutics, Albucasis Limited and sp2 Consulting Limited
AstraZeneca tipped to bid for US cancer specialist
AstraZeneca has reportedly held talks with San Francisco-based Medivation
Archive
Vast Resources PLC stays on podium as FTSE AIM 100 outpaces Footsie
In contrast to FTSE100, UK small caps were higher at the close, with Vast Resources still the top London gainer...
Aim stocks drift lower
Stocks on London's junior market are at least having a better time of it than the blue-chips
Sareum Holdings PLC wanted on approval for first trials
Sareum Holdings PLC shares shot up over 30% as the cancer drug specialist received the regulatory green light for clinical trials of its candidate CCT245737...
Risers and Fallers: Herencia Resources PLC, Electrocomponents PLC, AdEPT Telecom PLC...
Major share price risers and fallers in London at 3.30pm
Sareum Holdings PLC raises funds
The proceeds will be used to advance the company drug development programme
Risers & fallers: Ascent Resources PLC, Cadogan Petroleum PLC, CPPGroup PLC, Nyota Minerals PLC ...
Board room coups are in the offing at CPPGroup and Nyota Minerals.